Trial Profile
Phase I Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (ADIAtezoPemCarbo) (iTRAP Study)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Pegargiminase (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms iTRAP
- 24 Feb 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Apr 2018 New trial record